Mertelsmann R - Search Results

1

Minimal residual disease in autologous hematopoietic harvests from breast cancer patients.

Spyridonidis A, Bernhardt W, Fetscher S, Behringer D, Mertelsmann R, Henschler R. Spyridonidis A, et al. Among authors: mertelsmann r. Ann Oncol. 1998 Aug;9(8):821-6. doi: 10.1023/a:1008344708061. Ann Oncol. 1998. PMID: 9789603 Free article. Review.

2

Hematopoietic stem cell transplantation: more than just hematopoietic?

Spyridonidis A, Mertelsmann R, Finke J. Spyridonidis A, et al. Among authors: mertelsmann r. J Cancer Res Clin Oncol. 2004 Mar;130(3):127-34. doi: 10.1007/s00432-003-0507-x. Epub 2004 Jan 16. J Cancer Res Clin Oncol. 2004. PMID: 14727105 Review.

3

Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Fetscher S, Finke J, Engelhardt R, Mertelsmann R, Lange W. Fetscher S, et al. Among authors: mertelsmann r. Ann Hematol. 1997 Feb;74(2):73-7. doi: 10.1007/s002770050260. Ann Hematol. 1997. PMID: 9063376

4

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.

Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R. Fetscher S, et al. Among authors: mertelsmann r. Ann Oncol. 1997 Jan;8(1):49-56. doi: 10.1023/a:1008232329498. Ann Oncol. 1997. PMID: 9093707 Free article. Clinical Trial.

5

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.

Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R. Fetscher S, et al. Among authors: mertelsmann r. Ann Oncol. 1997 Jan;8(1):57-64. doi: 10.1023/a:1008209713568. Ann Oncol. 1997. PMID: 9093708 Free article. Clinical Trial.

6

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with second primary malignancies.

Fetscher S, Finke J, Engelhardt R, Mertelsmann R, Lange W. Fetscher S, et al. Among authors: mertelsmann r. Hematol Cell Ther. 1997 Apr;39(2):79-83. doi: 10.1007/s00282-997-0079-3. Hematol Cell Ther. 1997. PMID: 9168304

7

Supportive care in hematologic malignancies, including hematopoietic growth factors, transfusions, and infectious complications.

Fetscher S, Mertelsmann R. Fetscher S, et al. Among authors: mertelsmann r. Curr Opin Hematol. 1997 Jul;4(4):248-55. doi: 10.1097/00062752-199704040-00005. Curr Opin Hematol. 1997. PMID: 9260052 Review.

8

Hematopoietic cell proliferation and differentiation.

Spyridonidis A, Mertelsmann R, Henschler R. Spyridonidis A, et al. Among authors: mertelsmann r. Curr Opin Hematol. 1996 Jul;3(4):321-8. doi: 10.1097/00062752-199603040-00012. Curr Opin Hematol. 1996. PMID: 9372095 Review.

9

The clinical role of growth factors in the treatment of breast cancer.

Fetscher S, Mertelsmann R. Fetscher S, et al. Among authors: mertelsmann r. Biomed Pharmacother. 1998;52(3):101-8. doi: 10.1016/S0753-3322(98)80087-5. Biomed Pharmacother. 1998. PMID: 9755802 Review.

10

Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.

Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R. Fetscher S, et al. Among authors: mertelsmann r. Ann Oncol. 1999 May;10(5):561-7. doi: 10.1023/a:1026453922931. Ann Oncol. 1999. PMID: 10416006 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters